Zevra Q2 2026 Reacts on MIPLYFFA Sales
Zevra Therapeutics reported net revenue of $39.7 million for Q2 2026, driven by a 53% increase largely from MIPLYFFA sales.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day